Armata Pharmaceuticals filings document a NYSE American-listed biotechnology issuer developing bacteriophage-based product candidates for bacterial infections. Current reports on Form 8-K record FDA Fast Track and Qualified Infectious Disease Product designations for AP-SA02, financial-results releases, corporate updates, board appointments, annual meeting matters, and amendments to existing credit agreements with Innoviva Strategic Opportunities.
Proxy and governance filings cover board composition, director compensation, executive compensation disclosures, shareholder voting matters, and the company's common stock structure. Material-event filings also describe financing arrangements, warrant-related amendments, and furnished press releases tied to the AP-SA02 and AP-PA02 clinical-development platform.
Armata Pharmaceuticals, Inc. (ARMP) received $3.7 million in additional non-dilutive funding from the U.S. Department of War (DoW) for activities in the AP-SA02 Phase 3 development program. Armata said this is the first funding received specifically for Phase 3 execution under a previously announced DoW award. The award had previously provided $28.7 million, bringing cumulative non-dilutive DoW funding under the award to approximately $32.4 million.
The funding will support the Phase 3 clinical program for AP-SA02, an intravenous multi-phage candidate being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus. Armata plans a Phase 3 superiority study, anticipated to initiate in the second half of 2026.
Armata Pharmaceuticals, Inc. (ARMP) reports that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, its intravenously administered multi-phage product candidate, for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The designation is supported by the Phase 1b/2a diSArm study, in which AP-SA02 plus best available antibiotic therapy given every six hours for five days was well tolerated and showed higher and earlier clinical cure rates than placebo plus best available therapy. At the end-of-study assessment, 28 days after completion of antibiotics, 100% of AP-SA02 patients maintained clinical response without relapse versus 75% on placebo, with favorable trends in biomarkers such as CRP and IL-10. AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, and its development, including Phase 3 readiness, is partially supported by a $28.7 million Department of War award, with a Phase 3 superiority study in complicated SAB planned to begin in the second half of 2026.
Armata Pharmaceuticals reported a Q2 2026 net income of $74.1 million, driven almost entirely by a $91.0 million noncash gain from remeasuring a related-party Convertible Loan, despite its core operations remaining loss-making. Grant and award revenue was $2.5 million for the quarter, while research and development and general and administrative expenses rose to $7.6 million and $5.2 million, respectively, leading to a Q2 operating loss of $10.3 million and a $19.1 million operating loss for the first half of 2026.
As of June 30 2026, Armata held $24.0 million in cash and cash equivalents and $28.1 million including restricted cash, against $321.1 million in total liabilities, producing a stockholders’ deficit of $231.2 million. The company disclosed that existing cash will not fund operations for the 12 months following issuance of these statements, raising substantial doubt about its ability to continue as a going concern. To bolster liquidity, it drew a new $25.0 million term loan in May 2026 and raised about $2.4 million via its at-the-market equity program during the first half.
Armata continues late-stage development of bacteriophage therapies AP-PA02 and AP-SA02. AP-SA02 for complicated Staphylococcus aureus bacteremia has completed a Phase 1b/2a trial, received QIDP and Fast Track designations from the FDA, and has End-of-Phase 2 feedback supporting advancement to Phase 3, subject to securing additional funding.
Armata Pharmaceuticals reported second quarter 2026 results and provided an update on its bacteriophage pipeline. The company is preparing to initiate a pivotal Phase 3 superiority study of AP-SA02 for complicated Staphylococcus aureus bacteremia in the second half of 2026, following submission of the Phase 3 protocol to the FDA, completion of End-of-Phase 2 interactions, CMC progress, and FDA agreement on an Agreed Initial Pediatric Study Plan. AP-SA02 has Qualified Infectious Disease Product and Fast Track designations, and positive Phase 2a diSArm data were previously highlighted at IDWeek 2025.
For the quarter ended June 30, 2026, grant and award revenue was $2.5 million, up from $2.2 million a year earlier. Research and development expenses were $7.6 million and general and administrative expenses $5.2 million, resulting in a loss from operations of $10.3 million versus $6.8 million in 2025. Other income, net, was $84.5 million, primarily from a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by $6.6 million of interest expense. Net income was $74.1 million, or $2.02 per basic share and a $(0.27) loss per diluted share. Cash and cash equivalents were $24.0 million at June 30, 2026, up from $8.7 million at December 31, 2025, mainly reflecting a $25.0 million term loan, $2.4 million of at-the-market equity proceeds, and $1.2 million from stock option exercises, partly offset by cash used in operations.
Armata Pharmaceuticals, Inc. reported major progress advancing AP-SA02, its intravenously administered multi-phage therapy for complicated Staphylococcus aureus bacteremia, toward a planned Phase 3 superiority study intended to support a future Biologics License Application.
Armata highlighted submission of the complete Phase 3 protocol and comprehensive responses to all FDA End-of-Phase 2 comments, completion of four AP-SA02 engineering manufacturing runs, and plans to initiate the pivotal Phase 3 trial in the second half of 2026. The company also noted an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under that award to $28.7 million to support Phase 3 readiness, and announced the promotion of David House to Chief Financial Officer.
Armata Pharmaceuticals, Inc. promoted and appointed David House as Chief Financial Officer, effective July 17, 2026. House had been Senior Vice President, Finance and principal financial officer since August 2024 and will continue to report to the Chief Executive Officer.
Under a new employment letter, House receives an annual base salary of $371,315 and is eligible for a target annual bonus equal to 50% of base salary, with the percentage subject to future increases at the Board’s discretion. The compensation committee currently intends to grant him annual equity awards starting in 2026 with a grant date fair value of about $300,000, on terms consistent with other senior executives. If terminated without Cause or he resigns for Good Reason, he is eligible for 12 months of base-salary continuation, and time-based equity awards fully vest upon an involuntary termination occurring within one month before or 12 months after a Change in Control. The definition of “change in control” in Chief Business Officer Pierre Kyme’s agreement was also conformed to this standard.
Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx had 14,041 shares of common stock withheld on 2026-07-10 at $4.26 per share to satisfy income tax and withholding remittance obligations tied to the net settlement of restricted stock units. After this non-market, tax-withholding disposition, she directly holds 198,417 shares of Armata common stock.
Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has agreed to an Initial Pediatric Study Plan (Agreed iPSP) for AP‑SA02, a bacteriophage therapy being developed as an adjunct treatment for complicated Staphylococcus aureus bacteremia in pediatric patients.
The Agreed iPSP is a regulatory requirement before submitting a Biologics License Application and sets a framework for evaluating patients up to 17 years of age, aligned with the adult indication. Under FDA requirements and the Pediatric Research Equity Act, pediatric studies will be deferred until safety and efficacy data are generated in adults in a planned Phase 3 program expected to start in the second half of 2026. After completion of the adult Phase 3 study, Armata plans a single multicenter, open‑label pediatric study to assess safety, tolerability and clinical response.
AP‑SA02, a fixed multi‑phage cocktail targeting methicillin‑sensitive and methicillin‑resistant S. aureus, has Qualified Infectious Disease Product and Fast Track designations. Positive Phase 1b/2a diSArm study results were previously presented, and Armata plans a Phase 3 superiority study in complicated bacteremia, anticipated to initiate in the second half of 2026.
Armata Pharmaceuticals, Inc. filed an amended report to update details about new director Dr. Daniel Gilmer. The amendment explains that, effective June 24, 2026, the Board appointed Dr. Gilmer to its Nominating and Corporate Governance Committee. He will receive a $5,000 cash retainer for this committee role under the 2026 non-employee director compensation program, with the amount pro-rated based on his appointment date. All other information from the original report about his appointment to the Board remains unchanged.
Armata Pharmaceuticals reported that it received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense to support its lead bacteriophage candidate, AP-SA02. This increases the total DoD award to $28.7 million, aimed at advancing AP-SA02 for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA.
The new funds are intended to support Phase 3 readiness activities. Armata plans to initiate a Phase 3 superiority study of intravenous AP-SA02 in complicated SAB in the second half of 2026. AP-SA02 has Qualified Infectious Disease Product and Fast Track designations and previously generated positive Phase 2a results in the diSArm study.